Specified Patent definition

Specified Patent means United States Patent No. [*].

AI-Powered Contracts

Draft, Review & Redline at the Speed of AI

Specified Patent means [***].

Specified Patent means United States patent application number [commercially sensitive information redacted] (or any continuations, continuation-in-part or divisional applications thereof).

Examples of Specified Patent in a sentence

ONYX shall not enter into any settlement of any claim described in this Section 4.3.1 (Specified Patent Rights) that admits to the invalidity or unenforceability of the Specified Patent Rights, incurs any financial liability on the part of ▇▇▇▇▇ or requires an admission of liability, wrongdoing or fault on the part of ▇▇▇▇▇ without ▇▇▇▇▇’▇ prior written consent.
M.I.T. shall give good faith consideration to and effect any comments from COMPANY relating to the PATENT RIGHTS for cases other than the Specified Patent Rights, to the extent feasible, unless M.I.T. determines, in its sole discretion, that the acceptance of such comments would impair the rights of M.I.T. or any other licensee.
The Specified Patent Application contains enabling and best mode disclosures (as such terms are understood under 35 U.S.C. ss.
With respect to any French Intellectual Property, German (national) Patents, Korean Patents and Japanese Patents listed in a Quarterly New IP and Specified Patent Report, each Grantor shall comply with the requirements of Sections 4.3(a)(ii), 4.3(a)(iii)(B) and 4.3(b)(ii) within 30 days of delivery of the applicable Quarterly New IP and Specified Patent Report in order to ensure that the Collateral Agent has, or will have, a valid, perfected, first priority security interest in such Collateral.
If uniQure does not consent, then such uniQure Platform Patent Right or uniQure Manufacturing Specified Patent Right will cease to be a taken into account for the purposes of the calculation of the Royalty Term in Section 8.3.1 (Royalty Payments) and will be deemed to be expired for the purposes of the royalty step-down in Section 8.3.2(a) (Patent Expiration Step-Down).
Buyer is hereby authorized to continue such discussions on its own behalf with GSK, but neither Seller nor Buyer makes any representation or warranty with respect to the likelihood of being able to reach a satisfactory agreement with GSK or any other representation or warranty with respect to the Specified Patent or the underlying technology or intellectual property.
If Buyer fails to enter into such an agreement, Buyer shall have no rights to acquire, license or use the Specified Patent or use the cyclosporine compound.
The Company expects the Specified Patent Application to issue with such claims substantially intact, and, after reasonable search, knows of no reason why such claims should be finally rejected, and no reason why any such claims when issued in one or more U.S. patents would be invalid or unenforceable.
The parties acknowledge that Seller has been engaged in discussions with GlaxoSmithKline plc (“GSK”) to enter into a service agreement for work surrounding the Specified Patent.
In addition, uniQure will provide Partner with drafts of all proposed material filings and correspondence to any patent authority in its respective territory in connection with the Patent Prosecution of the uniQure Platform Patent Rights and uniQure Manufacturing Specified Patent Rights for Partner’s review and comment prior to the submission of such proposed filings and correspondence.

More Definitions of Specified Patent

Specified Patent means the patent application filed by Seller on June 30, 2015 as a US provisional, the subject matter of which is of novel compounds Seller has discovered in collaboration with Dr. Watashi (Tokyo) that prevent HBV infection into cells. The scope of such Specified Patent will be narrow due to the small number of compounds tested to date.

Specified Patent means, with respect to any Patent owned by any Grantor: (i) any Patent that has been identified through Parent and Borrower’s internal processes applied consistent with past practice as having a material Fair Market Value, including any such Patent that is subject to an anticipated or effected Patent Monetization Program; (ii) the Existing Material U.S. Patents; (iii) any U.S. Patent applications included in the Collateral; (iv) all Patents that belong to the same patent family as, or are a foreign counterpart of, any U.S. Patent described in clauses (i) or (ii) above; (v) any French Patents included in the Collateral; (vi) any Patent identified on Schedule 4.3(a)(iii)(A) or covered by Section 4.3(a)(iii)(B); (vii) any Patent that has been identified in writing by any Grantor to any third party as actually or potentially infringed by such third party; (viii) any Patent specifically identified in any written report submitted by Parent or Borrower to outside counsel for evaluation, other than licenses or sublicenses, including covenants-not-to-▇▇▇, which do not uniquely identify Patents; and (ix) any Patent identified as having actual or potential material Fair Market Value in a written valuation report prepared by Parent or Borrower or provided to Parent or Borrower by any third party purporting to have expertise in matters of valuation or assisting the Parent or Borrower in connection with a valuation study.